Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC) (Fulvestrant Intensity Density Study - Studio FIDeS)

NCT00927511 is registered in ClinicalTrials.gov with Regina Elena Cancer Institute as lead sponsor.

NCT NCT00927511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00927511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC) (Fulvestrant Intensity Density Study - Studio FIDeS)
Lead sponsor
Regina Elena Cancer Institute
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2008
Completion date
April 30, 2012
Enrollment
104 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer